Pharmacoeconomic evaluation of anti-diabetic therapy in a Nigerian tertiary health institution

Annals of African Medicine

Volumn 5, Issue 3, 2006, Pages 132-137

  Suleiman, I A ^a   Fadeke, O F ^a   Okubanjo, O O ^a  

^a OLABISI ONABANJO UNIVERSITY   (Nigeria)

Author keywords

Cost of illness analysis; Diabetes mellitus; Pharmacoeconomics

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BIGUANIDE; CAPTOPRIL; CHLORPROPAMIDE; FUROSEMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; INSULIN; LISINOPRIL; METFORMIN; METHYLDOPA; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC PATIENT; DIAGNOSTIC TEST; DISEASE DURATION; DRUG COST; DRUG SUBSTITUTION; ECONOMIC EVALUATION; EVIDENCE BASED PRACTICE; GLUCOSE BLOOD LEVEL; HEALTH CARE PERSONNEL; HOSPITAL COST; HOSPITAL PHARMACY; HUMAN; HYPERTENSION; INCIDENCE; INCOME; MANAGED CARE; NIGERIA; PATIENT TRANSPORT; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; RANDOM SAMPLE; RETROSPECTIVE STUDY; RISK REDUCTION; TERTIARY HEALTH CARE;

EID: 33947375623     PISSN: 15963519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Townsend R H. Post-marketing drug research and development. Drug Intelligence and Clinical Pharmacy 1987;21:134-136
2. World Health Organization. Health Economics, drug and health sector reform. WHO task force on health economics 1996
3. Cano SB, Crane VS. Conceptual model for assuring cost effectiveness in hospital pharmacy practice. Glaxo, 1989
4. Mayer H. Payers to use protocols to assess treatment plans. American Medical News 1998;1:41-44
5. Froemming SH, Cold JA, Wells BG. Pharmacoeconomic evaluations in medicine. DICP. Ann Phramacother 1989;23:431
6. Suleimam IA, Tayo F. Pharmacoeconomic evaluation of antibacterial utilization in primary, secondary and tertiary hospitals in developing economy. Nigerian Quarterly Journal of Hospital Medicine 2003;13:75-79
7. Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther 1993; 15:1121-1132
8. Drunmmond W. Cost of illness studies: a major headache? Pharmacoeconomics 1992;2:1-4
9. Lon NL. Cost determination and analysis. In: Bootman JL, Townsend RJ, McGhan WF (eds). Principles of pharmacoeconomics. Harvey Whitney, Cincinnati, 1996; 47-48
10. World Health Organization. Press release. 1998; WHO/63, 14th September
11. World Health Organisation. Prevention of diabetes mellitus. Report of WHO study group technical report, Ser, 1994 No. (144)
12. Owoaje EE, Rotimi CN, Kaufman JS, Tracy J, Cooper RS. Prevalence of adult diabetes in Ibadan, Nigeria. East Afr Med J 1997;74:299-302
13. Olatunbosun ST, Ojo PO, Fineberg NS, Bella AF. Prevalence of diabetes mellitus and impaired glucose tolerance in a group of urban adults in Nigeria. J Natl Med Assoc 1998;90:293-301
14. Obasohan AO, Enabulele JEE, Okokhere PO, Erhunmwunse RU. Abnormal glucose tolerance in "early" hypertension in Nigeria. Trop Cardiol 1997; 23: 46-49
15. O'Sullivan JB, Mahan CM. Prospective study of 352 young patients with chemical diabetes. N Engl J Med 1968; 278:1038-1041
16. Bakari AG, Onyemelukwe GC. Glucose Intolerance among apparently healthy Hausa-Fulani Northern Nigerians. Annals of African Medicine 2004;3:32-34
17. Nwafor A, Owhoji A. Prevalence of diabetes mellitus among Nigerians in Port Harcourt correlates with socio-economic status. Journal of Applied Sciences and Environmental Management 2001; 5:75-77
18. Unwin N, Alberti KGMM, Bhopal RS, Harland J, Watson W, White M. Comparison of the current WHO and new ADA criteria for the diagnosis of diabetes mellitus in three ethnic groups in the UK. Diabetic Med 1998; 1: 554-557
19. Adetuyibi A. Diabetes in Nigeria. African review of long term complications. Trop Geo Med 1976; 28: 155-168
20. Hamsten A, Steiner G. Non-insulin dependant diabetes mellitus and atherosclerosis, a hypoprotein perspective (editorial). J Intern Med 1994; 736 (suppl): 1-3
21. Roberts MJ. Work measurement. In: Brown TR, Smith MC (eds). Handbook of institutional pharmacy practice. Williams and Wilkins, Baltimore, 1986;90-110
22. Nertheimer AI. The defined daily dose system (DDD) for drug utilization review. Hospital Pharmacy 1986;21:233-241
23. American Diabetes Association. Treatment of hypertension in adult with diabetes. Diabetes Care 2003; 26 (suppl 1): 580-582 Pr.
24. Treatment of diabetic nephropathy and neuropathy. British National Formulary 1998; 36: 307
25. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2572
26. Technical report on Nigeria. United Nations Development Programme (UNDP), 2004
27. Gray A, Fenn P, McGuire A. The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabetic Med 1995;12:1068-1076
28. Nigerian poverty profile. Federal Office of Statistics, 1999;1980-1999
29. Robinson NLCESLK. Social deprivation and mortality in adults with diabetes mellitus. Diabetic Med 1998; 15: 205-212
30. Nilsson PM, Johansson S-E, Sundquist J. Low educational status is a risk factor for mortality among diabetic people. Diabetic Med 1998; 15: 213-219
31. Currie CJ, Kraus D, Morgan CL, Gill L, Stott NCH, Peters JR. NHS acute sector expenditure for diabetes: the present, future, and excess in-patient cost of care. Diabetic Med 1997; 14: 686-692
32. British Diabetic Association. Diabetes centres in the United Kingdom. Results of a survey of UK diabetes centres. London, 1998
33. Elmugarner IT, Zayat ASA, Hossain MM. Diabetes, obesity and hypertension in urban and rural people of Bedouin origin in the United Arab Emirates. J Trop Med Hyg 1995; 98: 407-415
34. Paterson KR. Population screening for diabetes mellitus. Diabetic Med 1993; 10: 777-781